Tirzepatide and metformin effects on hunger and BMI in an adolescent with hyperphagia and severe obesity due to MC4R Deficiency: a case report - PubMed
4 hours ago
- #pediatric obesity
- #MC4R deficiency
- #tirzepatide
- Tirzepatide, a dual GLP-1/GIP receptor agonist, was used alongside metformin in a 17-year-old girl with MC4R deficiency, the most common monogenic cause of obesity, to address hyperphagia and severe obesity.
- Initial treatment with tirzepatide (up to 12.5 mg weekly) led to substantial reductions in hyperphagia, less food noise, and prolonged satiety, but hunger scores increased again after 12 weeks, nearing pre-treatment levels by week 28.
- Adding metformin at week 28 resulted in a reduction in hyperphagia, and overall, the patient achieved significant weight loss: -13.9% of initial weight at 28 weeks and an additional -7% after metformin, totaling -20.9% by week 37, with no adverse effects reported at 41 weeks.
- While effective for weight loss in this adolescent case, the long-term effects of tirzepatide on hunger and satiety at higher doses remain uncertain, highlighting the need for cohort studies to assess safety and effectiveness in pediatric populations.